m6A 修饰在免疫逃避和免疫疗法中的作用。

IF 2.8 4区 医学 Q2 ONCOLOGY Medical Oncology Pub Date : 2024-05-18 DOI:10.1007/s12032-024-02402-9
Chunyu Wu, Lvyuan Li, Qiling Tang, Qianjin Liao, Pan Chen, Can Guo, Zhaoyang Zeng, Wei Xiong
{"title":"m6A 修饰在免疫逃避和免疫疗法中的作用。","authors":"Chunyu Wu, Lvyuan Li, Qiling Tang, Qianjin Liao, Pan Chen, Can Guo, Zhaoyang Zeng, Wei Xiong","doi":"10.1007/s12032-024-02402-9","DOIUrl":null,"url":null,"abstract":"<p><p>RNA modification has garnered increasing attention in recent years due to its pivotal role in tumorigenesis and immune surveillance. N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) modification is the most prevalent RNA modification, which can affect the expression of RNA by methylating adenylate at the sixth N position to regulate the occurrence and development of tumors. Dysregulation of m<sup>6</sup>A affects the activation of cancer-promoting pathways, destroys immune cell function, maintains immunosuppressive microenvironment, and promotes tumor cell growth. In this review, we delve into the latest insights into how abnormalities in m<sup>6</sup>A modification in both tumor and immune cells orchestrate immune evasion through the activation of signaling pathways. Furthermore, we explore how dysregulated m<sup>6</sup>A modification in tumor cells influences immune cells, thereby regulating tumor immune evasion via interactions within the tumor microenvironment (TME). Lastly, we highlight recent discoveries regarding specific inhibitors of m<sup>6</sup>A modulators and the encapsulation of m<sup>6</sup>A-targeting nanomaterials for cancer therapy, discussing their potential applications in immunotherapy.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Role of m<sup>6</sup>A modifications in immune evasion and immunotherapy.\",\"authors\":\"Chunyu Wu, Lvyuan Li, Qiling Tang, Qianjin Liao, Pan Chen, Can Guo, Zhaoyang Zeng, Wei Xiong\",\"doi\":\"10.1007/s12032-024-02402-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>RNA modification has garnered increasing attention in recent years due to its pivotal role in tumorigenesis and immune surveillance. N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) modification is the most prevalent RNA modification, which can affect the expression of RNA by methylating adenylate at the sixth N position to regulate the occurrence and development of tumors. Dysregulation of m<sup>6</sup>A affects the activation of cancer-promoting pathways, destroys immune cell function, maintains immunosuppressive microenvironment, and promotes tumor cell growth. In this review, we delve into the latest insights into how abnormalities in m<sup>6</sup>A modification in both tumor and immune cells orchestrate immune evasion through the activation of signaling pathways. Furthermore, we explore how dysregulated m<sup>6</sup>A modification in tumor cells influences immune cells, thereby regulating tumor immune evasion via interactions within the tumor microenvironment (TME). Lastly, we highlight recent discoveries regarding specific inhibitors of m<sup>6</sup>A modulators and the encapsulation of m<sup>6</sup>A-targeting nanomaterials for cancer therapy, discussing their potential applications in immunotherapy.</p>\",\"PeriodicalId\":18433,\"journal\":{\"name\":\"Medical Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-05-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12032-024-02402-9\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12032-024-02402-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

近年来,RNA修饰因其在肿瘤发生和免疫监视中的关键作用而受到越来越多的关注。N6-甲基腺苷(m6A)修饰是最常见的 RNA 修饰,它能通过甲基化第六个 N 位的腺苷酸来影响 RNA 的表达,从而调控肿瘤的发生和发展。m6A 的失调会影响促癌通路的激活,破坏免疫细胞功能,维持免疫抑制微环境,促进肿瘤细胞生长。在这篇综述中,我们将深入探讨肿瘤细胞和免疫细胞中 m6A 修饰异常如何通过激活信号通路来协调免疫逃避的最新见解。此外,我们还探讨了肿瘤细胞中失调的 m6A 修饰如何影响免疫细胞,从而通过肿瘤微环境 (TME) 内的相互作用调节肿瘤免疫逃避。最后,我们重点介绍了最近发现的 m6A 调节剂特异性抑制剂以及用于癌症治疗的 m6A 靶向纳米材料封装,并讨论了它们在免疫疗法中的潜在应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Role of m6A modifications in immune evasion and immunotherapy.

RNA modification has garnered increasing attention in recent years due to its pivotal role in tumorigenesis and immune surveillance. N6-methyladenosine (m6A) modification is the most prevalent RNA modification, which can affect the expression of RNA by methylating adenylate at the sixth N position to regulate the occurrence and development of tumors. Dysregulation of m6A affects the activation of cancer-promoting pathways, destroys immune cell function, maintains immunosuppressive microenvironment, and promotes tumor cell growth. In this review, we delve into the latest insights into how abnormalities in m6A modification in both tumor and immune cells orchestrate immune evasion through the activation of signaling pathways. Furthermore, we explore how dysregulated m6A modification in tumor cells influences immune cells, thereby regulating tumor immune evasion via interactions within the tumor microenvironment (TME). Lastly, we highlight recent discoveries regarding specific inhibitors of m6A modulators and the encapsulation of m6A-targeting nanomaterials for cancer therapy, discussing their potential applications in immunotherapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Medical Oncology
Medical Oncology 医学-肿瘤学
CiteScore
4.20
自引率
2.90%
发文量
259
审稿时长
1.4 months
期刊介绍: Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.
期刊最新文献
Incidence of lymphedema related to various cancers The Sirt1/Nrf2 pathway is a key factor for drug therapy in chemotherapy-induced cardiotoxicity: a Mini-Review Lipid metabolism reprogramming in renal cell carcinomas. Current diagnostic and quantitative techniques in the field of lymphedema management: a critical review. The role of IL-22 in cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1